The field of single-domain antibody (VHH) technology is rapidly evolving, with promising applications in cancer diagnostics, radiotherapy, and immunotherapy. One of the latest breakthroughs comes from Cortalix, a Dutch biotech startup, which has recently secured €1M in funding to accelerate the development and commercialization of its innovative single-domain antibody platform.

Cortalix: A New Player in the Single-Domain Antibody Landscape

Founded in 2023, Cortalix is based in Groningen, Netherlands, and specializes in developing single-domain antibodies for Positron Emission Tomography (PET) imaging diagnostics, radiotherapy, and CAR-T immunotherapy. Unlike traditional antibodies, single-domain antibodies—also known as nanobodies—offer higher stability, reduced production time, and greater flexibility, making them an ideal choice for next-generation medical applications.

The company’s platform enables the selection, production, and application of single-domain antibodies, providing an animal-free, cost-effective solution for the biotech and pharmaceutical industries. Cortalix’s expertise aligns well with the growing demand for more efficient and precise antibody-based therapeutics.

Strategic Partnerships and Industry Collaborations

Cortalix operates within the biomedical ecosystem of Northern Netherlands, working closely with leading institutions such as the University of Groningen (RUG), the University Medical Center Groningen (UMCG), and the LIFE Cooperative. In particular, its collaboration with UMCG focuses on advancing CAR-T cell therapy development, leveraging its single-domain antibody technology for targeted treatments to improve cancer care.

How the €1M Investment Will Be Used

The funding round was led by Future Tech Ventures, along with contributions from the Rabobank Innovation Loan and various subsidies. With this financial backing, Cortalix plans to expand its research and development efforts to refine its nanobody technology and bring it closer to clinical applications.

Herman Steen, CEO of Cortalix, stated, “This investment allows us to further refine our technology and prepare it for clinical applications. Our goal is to become a leading player in nanobody-based PET imaging, radiotherapy, and immunotherapy. This funding brings us a step closer to realizing that vision.”

Why This Matters for the Future of Nanobody Therapeutics

Nanobody technology is transforming the biotech and pharmaceutical landscape due to its unique structural advantages, including superior tissue penetration, high specificity, and strong binding affinity. As Cortalix enhances its humanized single-domain antibody libraries for radiopharmaceutical and CAR-T therapies, it moves closer to making nanobody-based treatments a clinical reality.

This development reinforces the growing importance of single-domain antibodies in precision medicine, particularly in cancer therapy, molecular diagnostics, and targeted drug delivery. With the support of Future Tech Ventures, Cortalix is well-positioned to contribute significantly to the future of antibody-based therapeutics.

Join the Nanobody Revolution

At AlpalifeBio, we are committed to advancing nanobody-based solutions for research and therapeutic applications. If your organization is exploring single-domain antibody technology, we would love to collaborate! Contact us today to learn how our Naïve Camelid VHH Antibody Phage Display Library can support your discovery and development efforts.

Stay tuned for more industry insights and innovations in nanobody technology!

Source: siliconcanals.com